Bessemer Group
EWTX icon

Bessemer Group’s Edgewise Therapeutics EWTX Stock Holding History

Bessemer Group’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17K Sell
426
-1,924
-82% -$66.3K ﹤0.01% 2032
2026
Q1 		$74K Hold
2,350
– – ﹤0.01% 1572
2025
Q4 		$58K Hold
2,350
– – ﹤0.01% 1605
2025
Q3 		$38K Buy
2,350
+2,165
+1,170% +$30.7K ﹤0.01% 1509
2025
Q2 		$2K Buy
+185
New +$2.67K ﹤0.01% 2199

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bessemer Group's EWTX Position: Q2 2026 in Review

Bessemer Group reduced its Edgewise Therapeutics (EWTX) stake by 82% in Q2 2026, selling an estimated $66.3K and leaving 426 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #2032.

Bessemer Group first reported a position in EWTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $74K in Q1 2026. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Bessemer Group held 426 shares of Edgewise Therapeutics worth $17K as of Q2 2026.
  • Bessemer Group sold 1,924 Edgewise Therapeutics shares in Q2 2026, an estimated $66.3K.
  • Edgewise Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2032 holding.
  • Bessemer Group first reported a position in Edgewise Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Bessemer Group's Edgewise Therapeutics position peaked at $74K in Q1 2026.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.